Tirzepatide 15 mg produced the largest HbA1c reduction (-2.24%) and weight loss (-8.74 kg) among seven diabetes medications compared in a network meta-analysis of 28 RCTs with 8,499 patients.
−8.74 kgweight loss with tirzepatide 15 mg vs placebo — the most among all 7 drugs compared
What the researchers found
Tirzepatide 15 mg reduced HbA1c by 2.24% and weight by 8.74 kg vs placebo — the most effective of all seven medications. Liraglutide outperformed SGLT2i for glycemia; SGLT2i excelled in blood pressure.
Why it matters
This is one of the first comprehensive network comparisons of tirzepatide against both GLP-1 agonists and SGLT2 inhibitors, helping clinicians choose the right medication based on each patient's primary treatment goals.
The numbers in context
Compared: tirzepatide, liraglutide, canagliflozin, ertugliflozin, empagliflozin, dapagliflozin, and henagliflozin. Searched through February 2024.
How the study worked
Bayesian network meta-analysis of 28 randomized controlled trials (8,499 participants) comparing tirzepatide (5/10/15 mg), liraglutide (1.2/1.8 mg), and five SGLT2 inhibitors for HbA1c, weight, blood pressure, and safety outcomes.
Who was studied
Adults with type 2 diabetes across multiple randomized trials
What this study cannot tell us
Network meta-analysis relies on indirect comparisons; trial populations differed; only studied as monotherapy add-ons (not combinations); short-term outcomes may not capture long-term cardiovascular benefits; SGLT2i cardiac and renal protection not captured by these endpoints.
How to read the evidence
Moderate evidence from a well-conducted network meta-analysis of 28 RCTs, limited by indirect comparisons and heterogeneity between trial populations.
When this study was published
Published in 2024 with literature through February 2024, providing a current comparison of the latest diabetes medication options.
The bigger picture
As the type 2 diabetes treatment landscape rapidly evolves with novel peptide-based therapies, head-to-head comparisons help clinicians navigate the expanding options and match medications to individual patient needs — prioritizing weight loss, glycemic control, or cardiovascular protection.
Questions still open
- How would tirzepatide compare to semaglutide directly in this framework?
- Do SGLT2 inhibitors' unique renal and heart failure benefits offset their lower glycemic efficacy?
- What is the optimal combination strategy when single agents aren't sufficient?
Common questions
Which diabetes medication works best for both blood sugar and weight loss?
Are SGLT2 inhibitors still worth taking compared to tirzepatide?
Read the original research
Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.
BMC endocrine disorders, 24(1), 278
Citation
Teng, Yunjie; Fan, Xue; Yu, Rui; Yang, Xiaoping. (2024). Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.. BMC endocrine disorders, 24(1), 278. https://doi.org/10.1186/s12902-024-01805-z